投资者关系活动记录表 证券代码：300485 证券简称：赛升药业 北京赛升药业股份有限公司 投资者关系活动记录表 编号：2023-002 | | 特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访  业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 活动参与人员 | 线上参与本公司 2022 年度网上业绩说明会的投资者 | | 时间 | 2023 年 04 月 13 日（星期四） | | 地点 | 公司通过全景网"全景•路演天下"（http://rs.p5w.net）采用 | | | 网络远程的方式召开业绩说明会 | | 上市公司 | 董事长兼总经理马骉先生，副总经理兼财务总监马丽女士，副总 | | 接待人员姓名 | 经理兼董事会秘书王雪峰先生，独立董事董岳阳先生，保荐代表 | | | 人赵轶女士 公司于 2023 年 04 月 13 日（星期四）15:00-17:00 采用网 | | | 络远程方式召开 2022 年度业绩网上说明会，就 2022 年度经营情 | | | 况与 ...

Financial Performance - The company's revenue for 2022 was approximately ¥734.55 million, a decrease of 30.10% compared to ¥1,050.81 million in 2021[31]. - Net profit attributable to shareholders was approximately ¥204.73 million, down 49.11% from ¥402.27 million in the previous year[31]. - The net cash flow from operating activities was approximately ¥110.43 million, a decline of 39.75% compared to ¥183.30 million in 2021[31]. - Basic earnings per share decreased to ¥0.43, down 48.81% from ¥0.84 in 2021[31]. - The company reported a significant drop in net profit excluding non-recurring gains and losses, which was approximately ¥330.39 thousand, down 99.68% from ¥104.34 million in 2021[31]. - The weighted average return on net assets was 6.18%, down from 13.47% in the previous year, reflecting a decrease of 7.29%[31]. - The company experienced a quarterly revenue decline in Q4 2022, with revenue of approximately ¥135.31 million, compared to ¥215.89 million in Q3 2022[33]. - The company achieved operating revenue of 734.55 million yuan, a decrease of 30.1% compared to the same period last year[62]. - The net profit attributable to shareholders was 204.74 million yuan, down 49.11% year-on-year[62]. - The gross profit margin for the pharmaceutical manufacturing sector was 77.03%, down 6.07% from the previous year[88]. - Sales volume in the pharmaceutical manufacturing sector dropped by 29.47% to 3,014.76 million units in 2022[90]. Dividend Distribution - The company reported a profit distribution plan, proposing a cash dividend of 0.86 CNY per 10 shares (including tax) based on a total of 481,666,400 shares[10]. - The total cash dividend for the year was 41,423,310.40 RMB, representing 100% of the total profit distribution[197]. - The cash dividend policy requires a minimum of 20% of profit distribution to be allocated as cash dividends during profit distribution[199]. - The board approved a profit distribution plan, distributing a cash dividend of 0.86 CNY per 10 shares, totaling 41,423,310.40 CNY[200]. - The company has no plans for stock dividends or capital increases in the current profit distribution[196]. Market and Industry Challenges - The pharmaceutical industry faces significant policy risks due to increasing government regulations and reforms, impacting market access and operational requirements[4]. - There is a risk of product price decline due to changes in drug procurement systems and medical insurance payment conditions, which could adversely affect profitability[6]. - The company’s marketing network covers major cities in China, but faces challenges in market expansion due to changing drug demand and increased competition[5]. - The pharmaceutical industry in China saw a revenue of approximately 29.11 trillion in 2022, a year-on-year decrease of 1.6%[42]. - The total profit for the pharmaceutical industry was approximately 4.29 billion, down 31.8% compared to the previous year, indicating significant pressure on profitability[42]. Research and Development - New drug development is a priority, but it involves lengthy processes and risks of failure, necessitating careful project selection and resource allocation[9]. - The company is committed to enhancing R&D capabilities and has plans to accelerate the development of new products and technologies[9]. - The company is actively involved in the development of new products, including a recombinant shingles vaccine that has entered clinical research in the U.S.[48]. - The company has established a proprietary biopharmaceutical purification technology platform, enhancing its core process technology advantages[59]. - The company is conducting preclinical research on a new cardiovascular drug aimed at improving microcirculation and is optimizing production processes[82]. - The company is advancing preclinical studies for a new thrombolytic drug, focusing on key process parameters and product stability[82]. - The company has established a platform for peptide drug design and synthesis, successfully completing the synthesis of target anti-tumor drugs[84]. - The company aims to apply for more than 2 invention patents this year while steadily advancing the progress of its R&D projects[135]. Strategic Initiatives - The company is exploring strategic partnerships or acquisitions to achieve its long-term goals in response to potential risks[10]. - The company is actively exploring potential mergers and acquisitions to enhance its market position and product offerings[31]. - The company aims to leverage its resources and expertise through strategic partnerships to enhance sustainable development and competitive advantage[45]. - The company is committed to expanding its market presence and enhancing its comprehensive competitive capabilities through strategic collaborations[74]. - The company is actively pursuing market expansion and investment opportunities through strategic acquisitions[180]. Human Resources and Talent Management - The company is focused on retaining core personnel to safeguard its technological capabilities amid increasing competition for talent[10]. - The company has implemented a talent cultivation plan with initial positive results, focusing on customized training for different talent types[139]. - The company has established a systematic internship base with universities to strengthen the training of technical employees and provide practical teaching opportunities[141]. - The company is optimizing its personnel structure by increasing the recruitment of employees with bachelor's degrees or higher and establishing a succession mechanism[140]. Operational Efficiency - The company has established a comprehensive procurement, production, and sales system to ensure operational efficiency[50]. - The company maintains an independent operational structure, with a complete production, sales, and R&D system, ensuring autonomous business capabilities[155]. - The company has established a complete and independent financial management system, with dedicated accounting personnel and independent tax obligations[156]. Governance and Compliance - The company has a clear governance structure with independent boards and committees, adhering to legal and regulatory requirements[156]. - The company’s board of directors includes experienced professionals, with the chairman and general manager holding significant shares, totaling 238,464,000 shares[161]. - The company has not reported any changes in the tenure of directors or senior management during the reporting period[162]. - The audit committee reviewed the 2021 fourth quarter audit report and fundraising account status[184]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 10% to 1.32 billion RMB, driven by new product launches and market expansion[167]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[167]. - The launch of two new products is scheduled for Q2 2023, anticipated to contribute an additional 200 million RMB in revenue[167].

出席本次年度网上说明会的人员有：公司董事长兼总经理马骉先生，副总经 理兼财务总监马丽女士，副总经理兼董事会秘书王雪峰先生，独立董事董岳阳先 生，保荐代表人赵轶女士。 为充分尊重投资者，提高交流的针对性，现就公司2022年度业绩网上说明会 提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023 年04月07日（星期五）12:00前访问https://ir.p5w.net/zj/，进入问题征集专 题页面进行提问。公司将在本次年度业绩说明会上对投资者普遍关注的问题进行 回答。 证券代码：300485 证券简称：赛升药业 公告编号：2023-018 北京赛升药业股份有限公司 关于举行 2022 年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京赛升药业股份有限公司(以下简称"公司")《2022年年度报告》及年度 报告摘要已于2023年03月30日刊登于中国证监会指定的创业板信息披露网站巨 潮资讯网（http://www.cninfo.com.cn）。 为使广大投资者进一步了解公司2022年经营情况，公司定于2023年04月 ...

投资者关系活动记录表 证券代码：300485 证券简称：赛升药业 北京赛升药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------|---------------------------------|---------------------------------| | \n投资者关系活动 | 编号： 2015001 \n■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 中邮基金 容杰 | | | 人员姓名 | 西南证券 何治力 | | | | 华商基金 张晓、陈恒 | | | | 中融人寿 汪虹、董凤亮 | | | | 银河证券 张金洋 | | | | 信达证券 李惜浣 | | | | 国寿安保基金 吴坚、王雪莹 | | | | 华夏基金 王泽实、张钧 | | | | 新华基金 潮礼君 | | 投资者关系活动记录表 | --- | --- | --- ...

投资者关系活动记录表 证券代码：300485 证券简称：赛升药业 北京赛升药业股份有限公司 投资者关系活动记录表 编号：2016001 | --- | --- | --- | |----------------|----------------------|------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 华创证券：张文录、宋凯、王逸萌、刘宇腾、故宏亮 | | | 嘉实基金：颜媛 | | | | 东兴基金：邓巧 | | | | 泓德基金：操昭煦 | | | | 长盛基金：张伟光 | | | | 浦银安盛：刘诗瑶 | | | 参与单位名称及 | 江铜集团：邢连云 | | | 人员姓名 | 中融人寿：汪虹 | | | | 中国人寿资产：赵文龙 | | | | 天风证券：王卓、贾帅 | | | | 华融 ...

Financial Performance - Revenue for Q3 2022 was CNY 215,891,125.90, a decrease of 24.92% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 18,443,537.92, down 64.79% year-on-year[3] - Basic earnings per share decreased by 63.64% to CNY 0.04[3] - The net profit for the third quarter of 2022 reached CNY 250,180,916.41, an increase of 88.17% compared to CNY 132,956,669.56 in the same period last year[10] - The total profit amounted to CNY 283,045,644.26, reflecting a growth of 79.19% from CNY 157,957,424.57 year-on-year[10] - The operating profit increased by 79.19% to CNY 283,067,954.35, driven by higher investment income from joint ventures and changes in the fair value of financial assets[10] - The company's basic earnings per share rose to CNY 0.52, marking a 79.31% increase from CNY 0.29 in the previous year[11] - Total operating revenue for the current period was ¥599,234,034.97, a decrease of 26.0% compared to ¥809,479,013.21 in the previous period[23] - Net profit for the current period was ¥250,180,916.41, an increase of 88.5% compared to ¥132,956,669.56 in the previous period[24] - The company reported a basic and diluted earnings per share of ¥0.52, up from ¥0.29 in the previous period[25] Assets and Equity - Total assets increased by 4.97% to CNY 3,570,725,389.62 compared to the end of the previous year[4] - Owner's equity attributable to shareholders rose by 5.40% to CNY 3,420,096,193.97[4] - Total assets rose to ¥3,570,725,389.62, compared to ¥3,401,649,422.52 in the previous period, reflecting a growth of 5.0%[21] - The company's total equity increased to ¥3,456,594,955.95 from ¥3,283,105,830.65 in the previous period[21] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 90,144,873.36, down 28.47%[3] - Cash and cash equivalents at the end of the period decreased by 69.72% to CNY 119,581,121.81, attributed to a reduction in cash reserves[12] - The company's cash and cash equivalents decreased from CNY 161,543,438.37 at the beginning of the year to CNY 119,581,121.81 by September 30, 2022, a decline of approximately 26%[19] - The net cash flow from operating activities for the current period is ¥90,144,873.36, a decrease of 28.5% compared to ¥126,025,973.11 in the previous period[26] - Cash and cash equivalents at the end of the period amount to ¥119,581,121.81, down from ¥394,967,167.05 in the previous period[27] Investment and Expenses - Investment income increased by 208.29% to CNY 90,531,418.02, mainly due to higher equity method investment income[9] - Sales expenses decreased by 31.18% to CNY 294,296,573.46, attributed to reduced marketing activities[9] - Research and development expenses were ¥79,555,905.38, slightly down from ¥80,473,801.38 in the previous period[23] - The company achieved an investment income of ¥90,531,418.02, significantly up from ¥29,365,431.82 in the previous period[24] Inventory and Liabilities - Inventory decreased by 30.61% to CNY 85,392,157.97, primarily due to reduced raw material purchases[9] - The total current assets decreased from CNY 1,530,193,553.81 to CNY 1,464,545,372.82, a reduction of about 4.3%[19] - Total liabilities decreased to ¥114,130,433.67 from ¥118,543,591.87 in the previous period[21] Strategic Developments - The company established a venture capital fund with an investment of CNY 10 million, and acquired an 18% stake in Beijing Haijing Biomedical Technology Co., Ltd. for CNY 7.2 million[15] - The company signed a strategic cooperation framework agreement with Beijing Tianguangshi Biotechnology Co., Ltd. to enhance collaboration in drug development and production[16] - The subsidiary Junyuan Pharmaceutical obtained a drug production license from the Liaoning Provincial Drug Administration[16] - The company is currently conducting Phase I clinical trials for a humanized anti-VEGF monoclonal antibody injection, which is a key product under development[17] Other Financial Metrics - Non-recurring gains and losses totaled CNY 7,781,671.26 for the current period[6] - The income tax expense rose by 31.45% to CNY 32,864,727.85, driven by the increase in profits[10] - The total comprehensive income for the period was CNY 253,797,441.83, an increase of 91.17% compared to CNY 132,759,296.71 in the previous year[11] - The cash paid for purchasing goods and services decreased by 32.32% to CNY 84,357,054.43, reflecting a reduction in raw material procurement[11] - The company experienced a foreign exchange impact on cash and cash equivalents of ¥2,457,965.42, compared to -¥134,172.85 in the previous period[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 34,687[13] - The largest shareholder, Ma Jiao, holds 49.51% of the shares, totaling 238,464,000 shares[13] Audit Status - The company has not undergone an audit for the third quarter report[28]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥521,930,586.60, representing a 7.72% increase compared to ¥484,520,630.90 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥85,333,463.28, a slight increase of 0.53% from ¥84,884,458.26 in the previous year[21]. - The net profit after deducting non-recurring gains and losses decreased by 32.89% to ¥51,614,391.46 from ¥76,915,530.41 in the same period last year[21]. - The net cash flow from operating activities was ¥82,364,563.18, down 42.08% from ¥142,201,118.48 in the previous year[21]. - The basic earnings per share remained unchanged at ¥0.18, consistent with the previous year[21]. - The diluted earnings per share also remained unchanged at ¥0.18, consistent with the previous year[21]. - The weighted average return on net assets was 3.01%, a decrease of 0.12% from 3.13% in the previous year[21]. - The total operating revenue for the first half of 2021 was CNY 521,930,586.60, an increase of 7.7% compared to CNY 484,520,630.90 in the first half of 2020[167]. - The company reported a net profit of 11,649,462.1 yuan for the first half of 2021, with total assets amounting to 22,608,698.7 yuan[89]. - The total comprehensive income for the first half of 2021 was CNY 81,788,656.96, compared to CNY 82,889,889.88 in the same period last year[169]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,026,206,534.72, an increase of 1.17% from ¥2,991,062,511.44 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company increased by 1.92% to ¥2,858,136,029.58 from ¥2,804,427,300.38 at the end of the previous year[21]. - The company's long-term equity investments increased to ¥468,016,729.95, accounting for 15.47% of total assets, up from 14.77% the previous year[57]. - Total liabilities decreased to CNY 125,784,628.92 from CNY 141,128,369.42, a reduction of about 10.9%[159]. - Owner's equity increased to CNY 2,900,421,905.80, up from CNY 2,849,934,142.02, representing a growth of approximately 1.8%[160]. - The cash and cash equivalents decreased significantly to CNY 376,546,597.51 from CNY 597,014,473.07, a decline of about 37.0%[162]. Research and Development - Research and development expenses surged by 125.08% to ¥56,488,696.35, reflecting the company's increased investment in ongoing research projects[50]. - The company is actively involved in the development of new products, including a recombinant shingles vaccine and a peptide drug for acute ischemic stroke[33]. - The company has established partnerships with several international medical system manufacturers for trade cooperation[32]. - The company has strengthened its R&D capabilities through partnerships with universities and research institutions, accelerating product development[43]. - The company has established a proprietary technology platform for the purification of biological macromolecules, which includes advanced techniques such as affinity chromatography and monoclonal antibody purification[46]. Market Position and Strategy - The company achieved over 50% market share in cardiovascular products and immunomodulators, establishing itself as a market leader[38]. - The sales model focuses on "on-site investment + academic promotion," with a distribution network targeting hospitals through distributors[36]. - The company is expected to maintain a significant market share in its immunomodulator products, particularly Thymosin Injection[38]. - The pharmaceutical industry in China has been experiencing continuous growth driven by increased medical demand and consumption upgrades[36]. - The company is exploring new investment opportunities to further strengthen its market position and financial performance[68]. Investment and Financial Management - The total amount of raised funds is CNY 1,080,944,700 after deducting issuance costs of CNY 72,855,300[75]. - Cumulative investment of raised funds reached CNY 708,010,000, with CNY 570,900,000 invested during the reporting period[74]. - The company invested CNY 463 million in bank wealth management products using raised funds, with a total of CNY 1.13 billion in wealth management products, and no overdue amounts reported[82]. - The company has made significant equity investments during the reporting period, including a long-term investment in Green Bamboo Bio-pharmaceutical Co., amounting to ¥20,000,000, representing a 9.82% stake[65]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period[84][85]. Compliance and Governance - The company is committed to adhering to the disclosure requirements set by the Shenzhen Stock Exchange for pharmaceutical and biological products[38]. - The company has established robust internal control systems and external audits to ensure the safety of its overseas assets[58]. - The company has ensured timely, accurate, and complete disclosure of the use of raised funds, with no violations reported[79]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[103]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[116]. Future Outlook - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[184]. - The management expressed optimism about future growth prospects despite the current financial challenges[184]. - The company is exploring strategic acquisitions to enhance its competitive position in the market[192]. - The company plans to expand its market presence and invest in new product development to drive future growth[192].

北京赛升药业股份有限公司 2021 年第三季度报告 一、主要财务数据 证券代码：300485 证券简称：赛升药业 公告编号：2022-032 北京赛升药业股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | --- | | | | 减 | | | 同期增减 | | 营业收入（元） | 342,775,244.87 | | 11.75% | 809,479,013 ...

Financial Performance - The company reported a profit distribution plan, proposing a cash dividend of 1.68 RMB per 10 shares based on a total of 481,666,400 shares[13]. - The company's operating revenue for 2021 was ¥1,050,805,089, a decrease of 3.97% compared to ¥1,094,225,280.40 in 2020[28]. - Net profit attributable to shareholders increased by 159.69% to ¥402,270,478.69 from ¥154,903,454.53 in the previous year[28]. - The net profit after deducting non-recurring gains and losses was ¥104,338,082.65, down 15.57% from ¥123,581,325.99 in 2020[28]. - The company's total assets increased by 13.73% to ¥3,401,649,422.52 at the end of 2021, compared to ¥2,991,062,511.44 at the end of 2020[28]. - Basic earnings per share rose by 162.50% to ¥0.84 from ¥0.32 in 2020[28]. - The company reported a net cash flow from operating activities of ¥183,295,288.13, a decrease of 30.50% from ¥263,725,621.99 in the previous year[28]. - The company reported non-recurring gains of ¥297,932,396.04 in 2021, significantly higher than ¥31,322,128.54 in 2020[34]. - The company achieved operating revenue of 1,050.81 million yuan, a decrease of 3.97% compared to the previous year, while net profit attributable to shareholders increased by 159.69% to 402.27 million yuan[59]. - The total revenue for the pharmaceutical manufacturing industry was approximately ¥1,049.66 million, accounting for 99.89% of total revenue, with a year-over-year decrease of 4.05%[76]. Research and Development - New drug development is a priority, but the company acknowledges the lengthy and uncertain nature of the process, which may impact operational costs and profitability[11]. - The company is focused on enhancing R&D capabilities and optimizing project selection to improve the success rate of new drug development[12]. - The company aims for an annual R&D investment growth of over 10% as part of its strategic goals during the "14th Five-Year Plan" period[38]. - The company emphasizes research and development, collaborating with academic institutions to accelerate product development[53]. - The company has established a proprietary biopharmaceutical purification technology platform, enhancing its production capabilities[54]. - The company has developed a key technology platform for antibody drugs, focusing on the discovery and research of new anti-tumor or immune-related antibodies[73]. - The company has established a platform for peptide drug design and synthesis, completing preliminary synthesis and process research for several anti-tumor drugs[73]. - The R&D department has filed 36 patents, with 17 patents granted during the reporting period[165]. - The management team emphasized a commitment to innovation, with a budget increase of 30% for R&D in 2022[166]. Market and Competition - The marketing network covers major cities in China, but the company anticipates challenges in market expansion due to evolving market demands and intensified competition[8]. - The company recognizes the potential for product price declines due to changes in procurement systems and increased competition in the market[9]. - The company is actively monitoring industry trends and may consider mergers or collaborations to achieve strategic goals[13]. - The company is focusing on internationalization in innovation, particularly in promoting traditional Chinese medicine abroad[38]. - The market for cardiovascular drugs is expected to expand due to an aging population, with projections indicating that by 2035, the population aged 65 and above in China will reach 210 million, accounting for 22.30% of the total population[42]. - The company is expanding its market presence through strategic partnerships and investments in biotechnology firms[53]. - The company is actively expanding its market presence through new product development and clinical trials, aiming to enhance its portfolio and revenue streams[72]. Product Development and Quality - The company emphasizes the importance of product quality, with a systematic quality control system in place to mitigate risks associated with complex production processes[10]. - The company is committed to increasing investment in product quality and accelerating the development of new products to meet regulatory requirements[10]. - The company has a diverse product pipeline with a balanced revenue contribution from various products, reducing reliance on any single product[53]. - The company focuses on the research, production, and sales of injectable drugs, with key products in cardiovascular, immune, and neurological disease treatments[43]. - The company has developed five national drug standard original research products, including fibrinolysin and its injection, and is the first in China to produce several key injectable drugs[44]. - The company’s immune regulation products include "Saiseng" and "Saisong" injections, targeting conditions such as progressive muscular dystrophy and chronic hepatitis[45]. - The company has completed the production registration application for a drug aimed at patients with bleeding tendencies, currently undergoing technical review[72]. - The company has prioritized rights for contract manufacturing and sales of BXOS110 project products post-approval, expanding its strategic development layout[68]. Governance and Management - The company has established a complete and independent financial management system, with dedicated accounting personnel and independent decision-making capabilities[146]. - The company ensures compliance with governance standards and has no significant discrepancies with regulatory requirements[143]. - The company has implemented performance evaluation and incentive mechanisms for senior management, ensuring transparency in appointments[142]. - The company actively engages with investors through various channels to enhance information transparency and investor relations[141]. - The board of directors consists of 8 members, including 3 independent directors, and held 13 meetings, reviewing 51 proposals[138]. - The company has expanded its board with independent directors who bring diverse expertise, including legal and financial backgrounds, to strengthen governance[158][159]. - The company has a clear focus on enhancing its market presence and operational efficiency through ongoing research and development initiatives[160]. Social Responsibility and Community Engagement - The company actively participated in social responsibility initiatives, donating a total of 100,000 RMB to aid flood relief efforts in Henan province[196]. - The company has established a partnership with Nanying Village in Pinggu District to support local economic development and poverty alleviation efforts[198]. - The company has implemented a GMP quality management system to ensure product quality and safety[196]. - The company has actively contributed to COVID-19 relief efforts by donating supplies to affected regions[196]. Strategic Investments and Acquisitions - The company has engaged in a merger and acquisition by acquiring a 3.077% stake in a biotechnology firm for ¥20,000,000[101]. - The company plans to focus on developing vaccines and treatments for various diseases through its recent acquisitions and investments[102]. - The company has completed two strategic acquisitions in the past year, enhancing its product portfolio and market reach[166]. - The company has signed a cooperation agreement with Lin Xuefang and Zhang Yi, indicating strategic partnerships for future growth[103]. Employee Development and Training - The company has implemented a flexible online training program for employees, including various training formats such as public courses and internal training[183]. - The company emphasizes the importance of talent development, implementing specific training plans for new graduates to ensure a strong talent pipeline for future growth[128]. - The total number of employees at the end of the reporting period is 584, with 447 in the parent company and 137 in major subsidiaries[180]. - The professional composition includes 172 production personnel, 82 sales personnel, 179 technical personnel, 14 financial personnel, and 137 administrative personnel[180].